{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:34:40Z","timestamp":1776270880685,"version":"3.50.1"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n American Indian and Alaska Native people have higher hepatitis C virus (HCV) incidence and mortality rates compared with other racial and ethnic groups. With the point-of-care HCV RNA diagnostic test recently approved for use in the US, the Cherokee Nation integrated diagnostic testing within existing community-based screening efforts to reach underserved community members.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe the lessons learned from implementing community-based point-of-care HCV RNA testing, including same-day HCV treatment uptake, in a tribal health setting.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This quality improvement study, conducted on the Cherokee Nation reservation in northeastern Oklahoma, collected quantitative data through paper-based surveys and electronic medical records from Cherokee Nation\u2019s Infectious Disease Department and harm reduction site, as well as qualitative data from staff meetings. Eligible participants included people aged 22 years or older who visited participating sites from October 30, 2024, to May 28, 2025, and provided informed consent.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n The Cherokee Nation Hepatitis C Engagement and Linkage Program.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Test acceptance, completion, validity, and results; HCV treatment uptake; and implementation lessons learned.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 400 participants (mean [SD] age, 42.5 [12.6] years; 209 [52%] women), 247 of 377 (66%) had a high school degree or less, 309 of 374 (83%) had an annual income of $15\u202f000 or less, and 149 of 385 (39%) reported ever injecting drugs. There were 405 point-of-care HCV RNA tests offered, and 348 (86%) accepted. Of these, 23 (7%) were not performed due to insufficient sample volume. An additional 51 samples (15%) tested were invalid. Of the 274 valid tests, 26 (10%) detected HCV. Of the samples with HCV, 12 (46%) were from American Indian and Alaska Native participants and 14 (54%) were not. Nine participants (35%) with detectable HCV initiated treatment, 6 (67%) the same day, and all who initiated treatment were American Indian and Alaska Native. Most invalid tests occurred within 2 months of implementation. Test validity increased after introducing techniques to improve volume collection.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this quality improvement study conducted in a tribal clinic and harm reduction site, point-of-care HCV RNA testing was feasible and effective, with high acceptance and same-day treatment among American Indian and Alaska Native participants. Staff training, addressing logistical barriers, and broadening the population reached supported equitable access to testing. This study supports expanding point-of-care HCV RNA testing and integrated treatment to advance HCV elimination.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.7242","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:30:22Z","timestamp":1776267022000},"page":"e267242","source":"Crossref","is-referenced-by-count":0,"title":["Point-of-Care Hepatitis C Testing in a Tribal Setting"],"prefix":"10.1001","volume":"9","author":[{"given":"Jorge","family":"Mera","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Cherokee Nation Health Services, Cherokee Nation Outpatient Health Center, Tahlequah, Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Blair","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cherokee Nation Health Services, Cherokee Nation Outpatient Health Center, Tahlequah, Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cherokee Nation Health Services, Cherokee Nation Outpatient Health Center, Tahlequah, Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savana","family":"Christy","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cherokee Nation Health Services, Cherokee Nation Outpatient Health Center, Tahlequah, Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Feder","sequence":"additional","affiliation":[{"name":"Sea Glass Group, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Comiford","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cherokee Nation Health Services, Cherokee Nation Outpatient Health Center, Tahlequah, Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"zoi260236r2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/liv.13647","article-title":"The next wave of hepatitis C virus: the epidemic of intravenous drug use.","volume":"38","author":"Shiffman","year":"2018","journal-title":"Liver Int"},{"issue":"6","key":"zoi260236r3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"zoi260236r7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/jvh.13399","article-title":"Loss to follow-up in the hepatitis C care cascade: a substantial problem but opportunity for micro-elimination.","volume":"27","author":"van Dijk","year":"2020","journal-title":"J Viral Hepat"},{"issue":"6","key":"zoi260236r8","doi-asserted-by":"publisher","first-page":"e1290","DOI":"10.1093\/cid\/ciab261","article-title":"Hepatitis C care cascades for 3 populations at high risk: low-income trans women, young people who inject drugs, and men who have sex with men and inject drugs.","volume":"73","author":"Facente","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi260236r9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/jvh.13437","article-title":"Hepatitis C testing and treatment uptake among young people who use opioids in New York City: a cross-sectional study.","volume":"28","author":"Kapadia","year":"2021","journal-title":"J Viral Hepat"},{"issue":"5","key":"zoi260236r10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/cid\/ciad503","article-title":"The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination.","volume":"78","author":"Kapadia","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"zoi260236r12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/infdis\/jiac049","article-title":"Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of hepatitis C virus RNA: a systematic review.","volume":"226","author":"Catlett","year":"2022","journal-title":"J Infect Dis"},{"issue":"11","key":"zoi260236r13","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1111\/liv.14983","article-title":"Outcomes of the CT2 study: a \u201cone-stop-shop\u201d for community-based hepatitis C testing and treatment in Yangon, Myanmar.","volume":"41","author":"Draper","year":"2021","journal-title":"Liver Int"},{"issue":"1","key":"zoi260236r14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-023-00780-3","article-title":"Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.","volume":"20","author":"Hassan","year":"2023","journal-title":"Harm Reduct J"},{"key":"zoi260236r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100490","article-title":"Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study.","volume":"22","author":"Lettner","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"zoi260236r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102608","article-title":"Time matters: point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England.","volume":"75","author":"Mohamed","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi260236r17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jhep.2023.04.019","article-title":"A \u201cone-stop-shop\u201d point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.","volume":"79","author":"Sheehan","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"zoi260236r18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/jvh.13268","article-title":"A same day \u201ctest and treat\u201d model for chronic HCV and HBV infection: results from two community-based pilot studies in Egypt.","volume":"27","author":"Shiha","year":"2020","journal-title":"J Viral Hepat"},{"issue":"3","key":"zoi260236r19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2468-1253(22)00346-6","article-title":"Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis.","volume":"8","author":"Trickey","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"zoi260236r20","author":"Finbraten","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"zoi260236r21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12954-023-00759-0","article-title":"A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa.","volume":"20","author":"Saayman","year":"2023","journal-title":"Harm Reduct J"},{"key":"zoi260236r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.103982","article-title":"Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: the TEMPO pilot study.","volume":"114","author":"Grebely","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi260236r23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jvh.13798","article-title":"Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days.","volume":"30","author":"Debette-Gratien","year":"2023","journal-title":"J Viral Hepat"},{"issue":"6","key":"zoi260236r24","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/liv.15266","article-title":"Peer support in small towns: a decentralized mobile hepatitis C virus clinic for people who inject drugs.","volume":"42","author":"Midgard","year":"2022","journal-title":"Liver Int"},{"issue":"12","key":"zoi260236r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30427","article-title":"Evaluation of the Cherokee Nation hepatitis C virus elimination program in the first 22 months of implementation.","volume":"3","author":"Mera","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260236r33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10877-018-0159-7","article-title":"Low temperature increases capillary blood refill time following mechanical fingertip compression of healthy volunteers: prospective cohort study.","volume":"33","author":"Shinozaki","year":"2019","journal-title":"J Clin Monit Comput"},{"issue":"1","key":"zoi260236r34","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2355566","article-title":"The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study.","volume":"56","author":"Giraldo","year":"2024","journal-title":"Ann Med"},{"key":"zoi260236r35","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1690448","article-title":"Outcomes of a tribal community program on hepatitis C, HIV, and syphilis screening, confirmation testing, and treatment initiation for an underserved population.","volume":"13","author":"Comiford","year":"2025","journal-title":"Front Public Health"},{"issue":"13","key":"zoi260236r37","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/ijerph16132345","article-title":"Factors correlating to the development of hepatitis C virus infection among drug users\u2014findings from a systematic review and meta-analysis.","volume":"16","author":"Zhou","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"zoi260236r38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings.","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"zoi260236r31"},{"key":"zoi260236r32","volume-title":"STAT-SAS, version 9.4","author":"SAS Institute","year":"2010"},{"key":"zoi260236r1","unstructured":"2023 Viral hepatitis surveillance report. Centers for Disease Control and Prevention. April 15, 2025. Accessed June 24, 2025. https:\/\/www.cdc.gov\/hepatitis-surveillance-2023\/about\/index.html"},{"key":"zoi260236r4","unstructured":"Behavioral health by race and ethnicity: results from the 2021-2023 national surveys on drug use and health (SAMHSA Publication No. PEP24-07-022). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2024. Accessed June 16, 2025. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47097\/2023-nsduh-race-eth-companion.pdf"},{"key":"zoi260236r5","unstructured":"2023 NSDUH annual national report. Substance Abuse and Mental Health Services Administration. July 30, 2024. Accessed June 11, 2025. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"zoi260236r6","unstructured":"Clinical screening and diagnosis for hepatitis C. Centers for Disease Control and Prevention. January 31, 2025. Accessed July 31, 2025. https:\/\/www.cdc.gov\/hepatitis-c\/hcp\/diagnosis-testing\/index.html"},{"key":"zoi260236r11","unstructured":"Cepheid receives CE-IVD clearance for Xpert HCV VL Fingerstick [press release]. Cepheid. September 19, 2018. Accessed July 31, 2025. https:\/\/cepheid.mediaroom.com\/2018-09-19-Cepheid-Receives-CE-IVD-clearance-for-Xpert-HCV-VL-Fingerstick"},{"key":"zoi260236r26","unstructured":"FDA permits marketing of first point-of-care hepatitis C RNA test. US Food and Drug Administration. June 27, 2024. Accessed June 5, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-first-point-care-hepatitis-c-rna-test"},{"key":"zoi260236r27","unstructured":"Cherokee Nation opens new harm reduction program. Anadisgoi. January 24, 2023. Accessed June, 5, 2025. https:\/\/anadisgoi.com\/index.php\/government-stories\/cherokee-nation-opens-new-harm-reduction-program"},{"key":"zoi260236r28","unstructured":"Cherokee Nation Health Services 2023 Annual Report. Cherokee Nation. Accessed June 5, 2025. https:\/\/health.cherokee.org\/media\/rynjpvrd\/health-services-annual-report-calendar-year-2023_apr-2-2.pdf"},{"key":"zoi260236r29","unstructured":"Agency overview. Indian Health Service. Accessed July 14, 2025. https:\/\/www.ihs.gov\/aboutihs\/overview\/"},{"key":"zoi260236r30","unstructured":"New patient packet binder. Cherokee Nation Health Services. January 2024. Accessed June 5, 2025. https:\/\/health.cherokee.org\/media\/wrjntoqv\/new-patient-packet-binder-92024-revised.pdf"},{"key":"zoi260236r36","unstructured":"Corcorran? MA, Kim? HN, Spach? DH. HCV simplified treatment. Hepatitis C Online. April 4, 2025. Accessed August 5, 2025. https:\/\/www.hepatitisc.uw.edu\/go\/test-cure\/hcv-simplified-treatment\/core-concept\/all"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847772\/mera_2026_oi_260236_1775667468.62558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:30:26Z","timestamp":1776267026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.7242","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}